PMID- 36311765
OWN - NLM
STAT- MEDLINE
DCOM- 20221101
LR  - 20221102
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 13
DP  - 2022
TI  - HLA Associations in pediatric autoimmune liver diseases: Current state and future 
      research initiatives.
PG  - 1019339
LID - 10.3389/fimmu.2022.1019339 [doi]
LID - 1019339
AB  - The strongest genetic association with autoimmunity is within chromosome 6p21, 
      where the human leukocyte antigen (HLA) complex resides. This review will focus 
      on the HLA associations within pediatric autoimmune hepatitis, autoimmune 
      sclerosing cholangitis and primary sclerosing cholangitis. In general, there is 
      considerable overlap in HLA genotypes conferring susceptibility to pediatric 
      autoimmune liver diseases, however unique HLA associations and protective HLA 
      genotypes exist. There are numerous areas for future research initiatives in 
      pediatric autoimmune liver diseases and HLA associations with clinical outcomes, 
      autoantigen discovery and novel therapeutics targeting the HLA- autoantigen- T 
      cell pathway will be highlighted.
CI  - Copyright (c) 2022 Mack.
FAU - Mack, Cara L
AU  - Mack CL
AD  - Department of Pediatrics, Division of Pediatric Gastroenterology, Hepatology & 
      Nutrition Medical College of Wisconsin and Children's Wisconsin, Milwaukee, WI, 
      United States.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220929
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Proteins)
RN  - 0 (Histocompatibility Antigens)
RN  - 0 (Autoantigens)
SB  - IM
MH  - Child
MH  - Humans
MH  - *Hepatitis, Autoimmune/genetics
MH  - *Cholangitis, Sclerosing/genetics
MH  - *Liver Diseases
MH  - Autoimmunity
MH  - Proteins
MH  - Histocompatibility Antigens
MH  - Autoantigens
PMC - PMC9609783
OTO - NOTNLM
OT  - T cell activation
OT  - autoimmune hepatitis
OT  - autoimmune sclerosing cholangitis
OT  - major histocompatibility complex (MHC)
OT  - primary sclerosing cholangitis
COIS- The author declares that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/11/01 06:00
MHDA- 2022/11/02 06:00
PMCR- 2022/01/01
CRDT- 2022/10/31 04:27
PHST- 2022/08/15 00:00 [received]
PHST- 2022/09/12 00:00 [accepted]
PHST- 2022/10/31 04:27 [entrez]
PHST- 2022/11/01 06:00 [pubmed]
PHST- 2022/11/02 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2022.1019339 [doi]
PST - epublish
SO  - Front Immunol. 2022 Sep 29;13:1019339. doi: 10.3389/fimmu.2022.1019339. 
      eCollection 2022.